IceCure Medical Ltd. (NASDAQ:ICCM)
| Market Cap | 2.48M-96.3% |
| Revenue (ttm) | 3.95M+41.6% |
| Net Income | -16.88M-8.3% |
| EPS | -6.76+19.3% |
| Shares Out | 2.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 98,914 |
| Open | 1.20 |
| Previous Close | 1.15 |
| Day's Range | 1.08 - 1.21 |
| 52-Week Range | 1.08 - 30.30 |
| Beta | 0.43 |
| Analysts | Buy |
| Price Target | 1.00(-9.09%) |
| Earnings Date | Nov 18, 2026 |
Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ICCM
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
$ICCM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ICCM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ICCM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ICCM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ICCM Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New ICCM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ICCM from public contracts
Source: USAspending.gov
ICCM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ICCM’s recent data — informational, not investment advice